279 related articles for article (PubMed ID: 15389810)
1. Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells.
Ohigashi T; Mizuno R; Nakashima J; Marumo K; Murai M
Prostate; 2005 Jan; 62(1):61-8. PubMed ID: 15389810
[TBL] [Abstract][Full Text] [Related]
2. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation.
Sharma M; Chuang WW; Sun Z
J Biol Chem; 2002 Aug; 277(34):30935-41. PubMed ID: 12063252
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the tumor suppressor gene phosphatase and tensin homologue partially inhibits wnt-1-induced mammary tumorigenesis.
Zhao H; Cui Y; Dupont J; Sun H; Hennighausen L; Yakar S
Cancer Res; 2005 Aug; 65(15):6864-73. PubMed ID: 16061670
[TBL] [Abstract][Full Text] [Related]
4. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
St-Germain ME; Gagnon V; Mathieu I; Parent S; Asselin E
Int J Oncol; 2004 May; 24(5):1311-24. PubMed ID: 15067356
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
[TBL] [Abstract][Full Text] [Related]
6. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis.
Chesire DR; Ewing CM; Gage WR; Isaacs WB
Oncogene; 2002 Apr; 21(17):2679-94. PubMed ID: 11965541
[TBL] [Abstract][Full Text] [Related]
7. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
She QB; Solit D; Basso A; Moasser MM
Clin Cancer Res; 2003 Oct; 9(12):4340-6. PubMed ID: 14555504
[TBL] [Abstract][Full Text] [Related]
8. Growth suppression activity of the PTEN tumor suppressor gene in human endometrial cancer cells.
Lilja JF; Wu D; Reynolds RK; Lin J
Anticancer Res; 2001; 21(3B):1969-74. PubMed ID: 11497285
[TBL] [Abstract][Full Text] [Related]
9. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
10. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
[TBL] [Abstract][Full Text] [Related]
11. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.
Urakami S; Shiina H; Enokida H; Kawakami T; Tokizane T; Ogishima T; Tanaka Y; Li LC; Ribeiro-Filho LA; Terashima M; Kikuno N; Adachi H; Yoneda T; Kishi H; Shigeno K; Konety BR; Igawa M; Dahiya R
Clin Cancer Res; 2006 Jan; 12(2):383-91. PubMed ID: 16428476
[TBL] [Abstract][Full Text] [Related]
13. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
[TBL] [Abstract][Full Text] [Related]
14. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
15. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth.
Edwards LA; Thiessen B; Dragowska WH; Daynard T; Bally MB; Dedhar S
Oncogene; 2005 May; 24(22):3596-605. PubMed ID: 15782140
[TBL] [Abstract][Full Text] [Related]
17. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression.
Huang H; Cheville JC; Pan Y; Roche PC; Schmidt LJ; Tindall DJ
J Biol Chem; 2001 Oct; 276(42):38830-6. PubMed ID: 11495901
[TBL] [Abstract][Full Text] [Related]
18. Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes.
Calastretti A; Gatti G; Quaresmini C; Bevilacqua A
Prostate; 2014 Oct; 74(14):1411-22. PubMed ID: 25111376
[TBL] [Abstract][Full Text] [Related]
19. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
[TBL] [Abstract][Full Text] [Related]
20. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
Lee S; Choi EJ; Jin C; Kim DH
Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
